Lambda Bence Jones Proteinuria C5139259
The presence of lambda-type light chains in the urine, which may indicate a plasma cell disorder. Further testing is needed to determine the underlying cause. Monitoring and treatment depend on the associated condition.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hypercalcemia
Proteinuria
Bone pain
(hematologic)Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Anemia
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Diagnostic bone marrow evaluation
Bone marrow biopsy and aspirate to determine plasma cell percentage, light chain type, and cytogenetic abnormalities for definitive diagnosis and staging.
Disease monitoring and surveillance
Serial serum free light chain testing, urine protein electrophoresis, and imaging studies to track disease progression and treatment response over time.
Additional treatment options
Plasma cell-directed therapy
Proteasome inhibitor-based or immunomodulatory therapy regimens targeting malignant plasma cell populations under oncology supervision.
medicationSupportive care medications
Bisphosphonates for bone disease, erythropoiesis-stimulating agents for anemia, and appropriate antimicrobial prophylaxis as indicated.
medicationRenal protection measures
Aggressive hydration, avoidance of nephrotoxic substances, and dietary modifications to protect kidney function during treatment.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Lambda Bence Jones Proteinuria C5139259?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
International Myeloma Working Group. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014.
Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013.
Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012.
Gertz MA, Comenzo R, Seldin DC, et al. Immunoglobulin light chain (AL) amyloidosis associated with plasma cell dyscrasia: a systematic review. Amyloid. 2019.
Medication Comparisons
Compare medications used to treat Lambda Bence Jones Proteinuria C5139259. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy